Century Therapeutics has emerged from stealth mode to develop a new generation of ‘off the shelf’ cancer cell therapies, with $250 million backing from investors including Bayer.
Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
With the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up of the most significant developments at this year’s event.